Odronextamab: a bispecific antibody for follicular lymphoma
Expert Opinion on Investigational Drugs · 03.07.2026 · 35 (7) · 489-497
DOI: 10.1080/13543784.2026.2689652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Investigational Drugs, online erschienen am 24.06.2026. Verfasst von Alejandro Martín García-Sancho und 2 weiteren Autor:innen. Beteiligte Einrichtung: IBSAL, Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, Follicular, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IBSAL, Cancer Research Center-IBMCC (USAL-CSIC), CIBERONC, University Hospital of Salamanca, Salamanca, Spain.
Zitieren
APA
Martín García-Sancho, A., Cabero-Martínez, A., & Gutiérrez, N. C. (2026). Odronextamab: a bispecific antibody for follicular lymphoma. Expert Opinion on Investigational Drugs, 35(7), 489-497. https://doi.org/10.1080/13543784.2026.2689652
Vancouver
Martín García-Sancho A, Cabero-Martínez A, Gutiérrez NC. Odronextamab: a bispecific antibody for follicular lymphoma. Expert Opinion on Investigational Drugs. 2026;35(7):489-497. doi:10.1080/13543784.2026.2689652
BibTeX
@article{MartnGarcaSancho2026,
author = {Martín García-Sancho, Alejandro and Cabero-Martínez, Almudena and Gutiérrez, Norma C},
title = {Odronextamab: a bispecific antibody for follicular lymphoma},
journal = {Expert Opinion on Investigational Drugs},
year = {2026},
volume = {35},
number = {7},
pages = {489--497},
doi = {10.1080/13543784.2026.2689652}
}
EUVIMED